阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

冠心病患者介入治疗前后焦虑抑郁障碍的心理干预与评价

Objective To discuss the effect of psychological intervention of depression in coronary heart disease after percutaneous coronary intervention (PCI). Methods The depression of 105 cases of coronary heart disease after PCI treatment was investigated. One hundred and five patients were randomly divided into intervention group and control group. The patientsin intervention group were treated with psychological intervention before and after PCI. The patients in control group were treated with normal treatment. Results There was not significant difference of incidence of depression an self-rating depression scale score between two groups. The depression in intervention group was less severe than that in control group ( P ＜ 0.01 ). Multivariate analysis showed: education level, the recent negative life events, household income, length of stay and sequelae of catheter intervention had significantly correlated with depression in coronary heart disease. Conclusion Psychological intervention can reduce the ratio of depression in coronary heart disease after PCI.     

冠心病患者介入治疗前后焦虑抑郁障碍的心理干预与评价

Objective To discuss the effect of psychological intervention of depression in coronary heart disease after percutaneous coronary intervention (PCI). Methods The depression of 105 cases of coronary heart disease after PCI treatment was investigated. One hundred and five patients were randomly divided into intervention group and control group. The patientsin intervention group were treated with psychological intervention before and after PCI. The patients in control group were treated with normal treatment. Results There was not significant difference of incidence of depression an self-rating depression scale score between two groups. The depression in intervention group was less severe than that in control group ( P ＜ 0.01 ). Multivariate analysis showed: education level, the recent negative life events, household income, length of stay and sequelae of catheter intervention had significantly correlated with depression in coronary heart disease. Conclusion Psychological intervention can reduce the ratio of depression in coronary heart disease after PCI.     

左冠状动脉主干狭窄的临床分析

目的探讨左主干狭窄的临床特点和治疗方法.方法分析左主干病变(狭窄≥50%)者和非左主干病变者临床资料.结果1 275例确诊的冠心病患者中,左主干狭窄74例(5.8%),非左主干病变180例(14.1%).左主干合并3支病变占66.2%,左主干病变组心绞痛发生率较非左主干病变组高.57例(77.0%)胸痛发作时心电图ST段下移≥0.2 mV.左主干并3支组与单纯左主干组比较心肌梗死发生率高(P＜0.05),左室射血分数低(P＜0.01).23例行CABG 1年内心绞痛症状消失或明显减轻,3例行无保护左主干直接支架术,术后半年心绞痛明显减轻.结论左主干狭窄者多合并其它冠脉病变,心绞痛严重.冠状动脉旁路移植术是最佳治疗手段.     

宝石能谱CT冠状动脉成像在冠心病诊断中的应用

目的 评价宝石能谱CT冠状动脉成像(CTA)在冠心病诊断中应用价值.方法 63例疑似冠心病分别接受CTA和冠状动脉造影检查,以冠状动脉造影结果为“金标准”对照,评估冠状动脉CTA检查的准确度.结果 冠状动脉CTA可以清晰显示冠状动脉狭窄病变,与冠状动脉造影相比,两者的符合率达96.0％.结论 CTA安全、简便和无创伤,对冠状动脉疾病具有较大的诊断价值.     

声学密度定量技术与冠状动脉造影术的对比研究

目的：探讨声学密度定量（AD）技术评价正常、狭窄及闭塞血管支配区域心肌的组织特征。方法：对疑诊冠心病的64例患者，根据冠状动脉造影结果将192支冠状动脉分组：正常组（A组）、狭窄组（B组）、闭塞组（C组），检测其相应血管支配区域心肌的背向散射积分参数。结果：与A组相比，B组心肌的背向散射积分的标化值（IBS％）增高；而背向散射积分周期变化幅度（CVIB）减小；C组心肌的IBS％增高更明显；CVIB减小也更明显。且14支闭塞血管支配区域心肌的CVIB曲线与正常节段呈反向，N－delay在B组及C组明显延长，同一参数组间比较差异均有显著性（P＜0．01），结论：AD技术能客观反映正常，狭窄及闭塞冠状动脉脉供血区域心域心肌的不同组织特性变化，对鉴别冠心病不同病变心肌的灌流特征具有一定的诊断意义。     

左室室壁瘤造影诊断分析

目的探讨室壁瘤形成与冠状动脉粥样硬化的关系，以及室壁瘤对心室功能的影响。方法采用冠状动脉造影方法对168例临床疑诊冠心病患者进行检查。结果发现室壁瘤26例，其中冠状动脉单支病变11例，双支7例，三支7例，冠状动脉正常1例，受累血管狭窄程度均在III级以上。室壁瘤累及心室壁一段、二段、三段及四段的左室射血分数分别平均为(50±31)％、(32±16)％、(29±21)％及(18±14)％(r=-0.65，P     

经皮冠状动脉介入治疗79例临床分析

目的探讨经皮冠状动脉介入治疗的可行性、安全性和成功率。方法选择该院2005年1月~2009年7月经皮股动脉穿刺冠状动脉腔内成形术（PTCA）及支架术79例患者为研究对象。结果A型病变支架术成功率100%（36/36）,B型病变成功率98.9%（88/89）,C型病变成功率95.3%（41/43）。1例分叉、弯曲、偏心性病变和2例慢性闭塞性病变（CTO）因指引导丝不能通过病变致手术失败,总成功率为98.2%。结论经皮冠状动脉介入治疗创伤小,恢复快,安全且成功率高。     

冠心病住院患者冠状动脉介入诊疗依从性的初步研究

目的探讨影响冠心病患者对冠状动脉介入诊疗的依从性的主要因素。方法回顾性分析2008年10月至2009年7月间我科住院的临床诊断为冠心病的505名患者,观察资费来源、冠心病亚型及年龄阶段三个不同因素对住院期间冠状动脉介入诊疗依从性的影响。结果随着年龄的增长,对冠状动脉介入的依从性逐步减低;军队医保组与自费组较社会医保组依从性较高;疾病类型对介入依从性影响则相对较小。结论在当前医疗保障体制下,心脏冠状动脉介入诊疗的依从性明显受到包括医疗资源保障程度、年龄阶段等多种因素的影响。